Home › Funds › Castle Hook Partners LP › NAMS
Castle Hook Partners LP position in NAMS
NEWAMSTERDAM PHARMA COMPANY · Health Care
Castle Hook Partners LP reported holding 1,371,005 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q2 2026 13F filing — a position valued at US$46.5M, representing 0.21% of its reported portfolio and ranking #45 among its reported holdings. Castle Hook Partners LP has disclosed NAMS holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Castle Hook Partners LP's NAMS position evolved
Castle Hook Partners LP first disclosed a stake in NAMS in Q4 2025 at 1,085,008 shares (US$38.1M). The position peaked in Q2 2026 at 1,371,005 shares, worth US$46.5M. Across 3 filings, Castle Hook Partners LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,371,005 shares valued at US$46.5M — an increase of 328,368 shares quarter over quarter.. Notable position changes include a 31% increase in Q2 2026 (shares fell 32% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.09M | $38.06M | New |
| Q1 2026 | 1.04M | $33.37M | Reduce |
| Q2 2026 | 1.37M | $46.46M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NAMS and 13F data
NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 43 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NAMS
- Frazier Life Sciences Management, L.P. 18.09M sh · $613.03M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 9.55M sh · $323.66M · Q2 2026
- FCPM III SERVICES B.V. 8.49M sh · $287.74M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.26M sh · $144.53M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 3.81M sh · $129.00M · Q2 2026
- Maverick Capital 3.27M sh · $110.75M · Q2 2026
- MAVERICK CAPITAL LTD 3.27M sh · $110.75M · Q2 2026
- Duquesne Family Office LLC 3.07M sh · $104.05M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 2.21M sh · $74.85M · Q2 2026
- NWI MANAGEMENT LP 702.00K sh · $23.79M · Q2 2026
- Rock Springs Capital Management LP 582.74K sh · $19.75M · Q2 2026
- First Turn Management, LLC 582.50K sh · $19.74M · Q2 2026
More on Castle Hook Partners LP
FAQ
How long has Castle Hook Partners LP held NAMS?
Castle Hook Partners LP has disclosed NAMS holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Castle Hook Partners LP's current position in NAMS?
As of Q2 2026, Castle Hook Partners LP holds 1.37M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $46.46M, representing 0.21% of its reported portfolio and ranking #45.
Has Castle Hook Partners LP been buying or selling NAMS?
In the latest 13F filing (Q2 2026), Castle Hook Partners LP increased its position in NAMS. The position peaked in Q2 2026 at 1.37M shares.
Which other funds hold NAMS?
Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.